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Abstract 
Background 
Gastric cancer is the second most common cause of cancer-related death in the world. 
Inflammatory signals originating from gastric cancer cells are important for recruiting 
inflammatory cells and regulation of metastasis of gastric cancer. Several microRNAs 
(miRNA) have been shown to be involved in development and progression of gastric cancer. 
miRNA-146a (miR-146a) is a modulator of inflammatory signals, but little is known about its 
importance in gastric cancer. We therefore wanted to identify targets of miR-146a in gastric 
cancer and examine its biological roles. 
Results 
The expression of miR-146a was evaluated by quantitative PCR (qPCR) and found up-
regulated in the gastrin knockout mice, a mouse model of gastric cancer, and in 73% of 
investigated human gastric adenocarcinomas. Expression of miR-146a by gastric cancer cells 
was confirmed by in situ hybridization. Global analysis of changes in mRNA levels after 
miR-146a transfection identified two transcripts, caspase recruitment domain-containing 
protein 10 (CARD10) and COP9 signalosome complex subunit 8 (COPS8), as new miR-146a 
targets. qPCR, Western blotting and luciferase assays confirmed these transcripts as direct 
miR-146a targets. CARD10 and COPS8 were shown to be part of the G protein-coupled 
receptor (GPCR) pathway of nuclear factor-kappaB (NF-kappaB) activation. 
Lysophosphatidic acid (LPA) induces NF-kappaB activation via this pathway and over-
expression of miR-146a inhibited LPA-induced NF-kappaB activation, reduced LPA-induced 
expression of tumor-promoting cytokines and growth factors and inhibited monocyte 
attraction. 
Conclusions 
miR-146a expression is up-regulated in a majority of gastric cancers where it targets 
CARD10 and COPS8, inhibiting GPCR-mediated activation of NF-kappaB, thus reducing 
expression of NF-kappaB-regulated tumor-promoting cytokines and growth factors. By 
targeting components of several NF-kappaB-activating pathways, miR-146a is a key 
component in the regulation of NF-kappaB activity. 
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Background 
Globally gastric cancer is the second most common cause of cancer-related death [1]. 
Development of gastric cancer is influenced by interactions between host, environmental and 
bacterial factors. Examples of synergistic risk factors for gastric cancer are polymorphisms in 
genes involved in the host inflammatory response [2], Helicobacter pylori (H. pylori) 
virulence factors [3] and diets rich in salt and nitrate [4]. Despite recent progress in detection 
and treatment of early gastric cancer, the long-term survival rate for advanced gastric cancer 
is low [5]. The main challenges in treatment of advanced gastric cancer are lymphatic, 
peritoneal or distant organ metastases, which simultaneously predict poor outcome for these 
patients [6]. 
Although many oncogenes and tumor suppressors have been reported to be involved in 
development of gastric carcinomas, the molecular mechanisms underlying metastasis of 
advanced gastric carcinomas are still poorly understood [7]. One of the key events in gastric 
carcinogenesis is inflammation. Inflammation leads to activation of the transcription factor 
nuclear factor-kappaB (NF-κB), which is associated with gastric carcinogenesis [8,9]. 
microRNAs (miRNA) are involved in the development and progression of gastric cancer [10-
13]. miRNA is a class of endogenous, non-coding, single-stranded RNA molecules of app. 22 
nucleotides that mediate post-transcriptional regulation of gene expression through base 
pairing with the 3’ untranslated region (UTR) of target messenger RNA (mRNA) [14]. 
miRNAs are involved in regulation of most cellular processes including cell proliferation, 
migration, differentiation and apoptosis [10,14,15]. miRNAs are aberrantly expressed in most 
human cancers and, like protein-coding genes, miRNAs can function as either tumor 
suppressors or oncogenes, thereby regulating carcinogenesis [10,12]. miRNA-146a (miR-
146a) is regulated by NF-κB and inhibits interleukin-1 receptor (IL-1R) and toll-like receptor 
(TLR)- induced activation of NF-κB by targeting interleukin-1 receptor-associated kinase 1 
(IRAK1) and TNF receptor associated factor 6 (TRAF6) [16-18]. miR-146a has been 
reported aberrantly expressed in several inflammatory diseases and cancers, but the role of 
miR-146a in gastric cancer is still controversial, as expression of miR-146a has been found 
both up- and down-regulated here [19-24]. Therefore, we investigated the expression of miR-
146a in gastric cancer and characterized its targets and molecular functions to clarify the 
contradictory findings. 
We found that miR-146a is up-regulated in a mouse model of gastric cancer as well as in 
human gastric adenocarcinomas and identified CARD10 and COPS8 as new direct targets of 
miR-146a. Both are part of the G protein-coupled receptor (GPCR)-mediated signal 
transduction that mediates activation of NF-κB. This suggests that miR-146a acts tumor 
suppressing by inhibiting GPCR-mediated activation of NF-κB and the resulting expression 
of tumor-promoting cytokines and growth factors. 
Results 
miR-146a expression is up-regulated in a mouse model of gastric cancer and 
in human gastric adenocarcinomas 
Gastrin knockout (KO) mice are achlorhydric and develop intestinal metaplasia and gastric 
adenomas over time [25]. Using quantitative PCR (qPCR) we found the expression of miR-
146a app. 2-fold up-regulated in old gastrin KO mice with either fundic intestinal metaplasia 
or antral adenoma compared to the expression in wild type (WT) mice (P < 0.05) (Figure 1A). 
Using in situ hybridization miR-146a was detected in metaplastic gastric tissue from the 
gastrin KO mice, but not in normal gastric tissue from the WT mice (Figure 2AB) 
(Additional file 1: Figure S1). Having established that miR-146a is increased in our mouse 
model of gastric cancer we examined expression of miR-146a in paired human gastric 
adenocarcinomas and adjacent control biopsies and found that it was up-regulated in 27 out 
of 37 cases (73%) (Figure 1B). In situ hybridization showed that miR-146a was expressed by 
the human gastric adenocarcinoma cells, while miR-146a-positive cells were not detected in 
the normal gastric mucosa (Figure 2CD) (Additional file 1: Figure S1). 
Figure 1 Increased expression of miR-146a in the gastrin KO mouse gastric cancer 
model and human gastric cancer. (A) The relative expression of miR-146a in metaplastic 
fundic tissue (n = 8) and hyperplastic antral mucosa (n = 4)/antral adenomas (n = 4) from 
gastrin knockout (KO) mice compared to the average expression in matching wild type (WT) 
mouse tissue. * = P < 0.05. (B) Waterfall plot of the expression of miR-146a in 37 human 
gastric adenocarcinomas relative to the expression in adjacent normal tissue. miR-146a was 
up-regulated in 27 out of 37 tumors (73%). The expression levels of miR-146a were 
determined by qPCR and normalized to those of the endogenous control RNU44 
Figure 2 In situ hybridization detection of miR-146a expression in the gastrin KO 
mouse gastric cancer model and human gastric cancer. (A) Expression of miR-146a was 
not detected in WT fundic mouse tissue, (B) while miR-146a-positive cells (blue nuclei) were 
detected in the metaplastic fundic tissue from gastrin KO mice. (C) No signal was detected 
with the scrambled LNA probe. (D) miR-146a expression was absent in normal human 
gastric tissue, (E) but present in human gastric adenocarcinoma cells (blue nuclei). (F) 
Negative control using a scrambled LNA probe. Representative miR-146a-positive cells are 
indicated by arrows. Original magnification x20, Scale bar = 100 μm 
There was no correlation between miR-146a expression in gastric adenocarcinomas and 
patients’ age, sex and localization or classification of tumors (data not shown). Although 
patients with high miR-146a expression seemed to have a better overall survival this was not 
significant (Additional file 1: Figure S2). 
miR-146a targets members of the GPCR-mediated NF-κB activation pathway 
Having demonstrated increased expression of miR-146a in the majority of gastric cancers, we 
wanted to establish the biological actions of miR-146a by characterizing its direct molecular 
targets in human gastric cancer. We wanted to do this by over-expressing miR-146a in gastric 
cancer cells and then identifying mRNAs with reduced expression [26]. Therefore, we 
examined miR-146a expression in a panel of cell lines and found varied, but surprisingly low 
expression of miR-146a in the available gastric cell lines (Additional file 1: Figure S3), 
considering the detected over-expression in tumors. 
The human gastric cancer cell line SNU638, which has neglectable levels of endogenous 
miR-146a was found suited for miR-146a over-expression studies. Since miR-146a 
expression was very low in the tested gastric cell lines miR-146a inhibition studies were not 
conducted. 
We first tested if over-expression of miR-146a affected the growth of the SNU638 cells and 
found cell growth unaffected (Additional file 1: Figure S4). Subsequently, global changes in 
gene expression in SNU638 cells following over-expression of miR-146a were examined. 
After miR-146a transfection mRNAs with predicted 3’UTR miR-146a target sites were 
significantly down-regulated compared to mRNAs without predicted targets sites (P < 4.6e-
11, two-tailed Wilcoxon rank-sum test) (Figure 3A). We analyzed all words of length 5–7 for 
over-representation in down-regulated mRNAs after miR-146a transfection and found the 
word strongest correlated with down-regulation was the seed site complementary to mature 
miR-146a bases 2-7/8 (Figure 3B). Transcripts with predicted 3’UTR miR-146a target sites 
that were significantly down-regulated upon miR-146a transfection were regarded as 
potential direct miR-146a targets. 847 matched these criteria (Additional file 1: Table S5). 
The top 10 most down-regulated potential miR-146a targets are shown in Figure 3C. As a 
negative validation control we repeated the procedure treating SNU638 cells with a miR-146a 
LNA inhibitor. There was no significant up-regulation of genes with the seed site 
complementary to mature miR-146a bases (data not shown). 
Figure 3 Identification of miR-146a targets. (A) Predicted miR-146a target transcripts are 
significantly down-regulated after miR-146a transfection compared to expressed genes that 
are not predicted targets of miR-146a (P < 4.6e-11, two-tailed Wilcoxon rank-sum test). (B) 
Top 10 words most correlated with down-regulation (correlation Z-scores are indicated to the 
left of each word, all 10 words have an estimated FDR < 1e-6). Capital letters highlight the 
miRNA seed region, Watson-Crick base-pairs (blue), mismatches (red). The word strongest 
correlated with down-regulation was the seed site complementary to mature miRNA bases 2-
7/8. (C) Transcripts, having 6mer or 7mer miR-146a seed sites in the 3’UTR, that are most 
down-regulated upon miR-146a transfection are shown. These are potential direct miR-146a 
targets. Expression is given in log2 fold change. The 3’UTR 6 m/7 m columns indicate 
numbers of 6- or 7mer miR-146a seed sites in the 3’UTR 
The three most down-regulated genes upon miR-146a over-expression, IRAK1, caspase 
recruitment domain-containing protein 10 (CARD10) and COP9 constitutive 
photomorphogenic homolog subunit 8 (COPS8) (Figure 3C) all belong to signaling pathways 
leading to NF-κB activation [27-29]. IRAK1 is a known miR-146a target involved in TLR- 
and IL-1R-mediated activation of NF-κB [16-18]. CARD10 is involved in GPCR-mediated 
activation of NF-κB [27], while COPS8 is thought to be involved in this pathway based on its 
involvement in T cell receptor (TCR)-mediated NF-κB activation [28]. Surprisingly, but 
similar to the findings of Boldin et al. [30], expression of TRAF6, which has previously been 
described as a miR-146a target [16,18,31], was not reduced at the transcriptional level after 
miR-146a over-expression in our model system. 
In gastric cancer, NF-κB modulates cell survival, immunity and inflammation, and NF-κB 
activation is associated with poor outcome in gastric cancer [32,33]. We therefore focused on 
characterizing CARD10 and COPS8 as direct miR-146a targets and their roles in NF-κB 
activation in gastric cancer. We confirmed miR-146a-mediated down-regulation of CARD10, 
COPS8 and IRAK1 at the transcript level (Figure 4A) and also found that miR-146a reduced 
levels of CARD10, COPS8 and IRAK1 protein (Figure 4B). Finally, direct targeting of miR-
146a to 3’UTRs of the target genes was demonstrated using luciferase assays (Figure 4C). In 
summary, we confirmed earlier observations showing that miR-146a directly targets IRAK1 
and we furthermore identified two new targets, CARD10 and COPS8, which codes for 
proteins suggested to be involved in NF-κB activation. COPS8 is a component of the COP9 
signalosome which consists of eight subunits (GPS1 and COPS2-8) [34]. COPS8 is the only 
subunit targeted directly by miR-146, but since alteration in the amount of the individual 
subunits has been shown to affect the amount of other subunits [35,36], we examined how 
transfection with miR-146a affected expression of all COP9 signalosome components. In 
unstimulated cells the expression of COPS2 was reduced (20%) (Additional file 1: Figure 
S5). We therefore assume that the effects of miR-146a on the COP9 complex mainly result 
from a reduction in COPS8 expression, although indirect destabilization of the complex 
cannot be ruled out. 
Figure 4 CARD10 and COPS8 are direct miR-146a targets. (A) mRNA expression of the 
two new miR-146a targets, CARD10 and COPS8, and IRAK1, a known miR_146a target, 
was determined by qPCR in control- and miR-146a-transfected SNU638 cells. Expression of 
each transcript is shown relative to the expression in control-transfected cells. CARD10, 
COPS8 and IRAK1 expression was down-regulated following miR-146a over-expression. 
Data are shown as mean ± S.D. of four biological replicates. * = P < 0.05, ** = P < 0.01, 
*** = P < 0.001. (B) miR-146a transfection also reduced the protein levels of CARD10, 
COPS8 and IRAK1 in miR-146a-transfected SNU638 cells. The expression of each protein is 
shown relative to the expression in control-transfected cells. Bands were quantified relative to 
β-actin. Data are shown as mean ± S.D. of four biological replicates. * = P < 0.05, 
** = P < 0.01, *** = P < 0.001. (C) Verification of direct and functional target binding using 
luciferase constructs holding WT 3’UTRs and mutated (Mut) 3’UTRs (the central 4 
nucleotide were replaced in miR-146a binding site) for CARD10, COPS8 and IRAK1. 
Constructs containing either WT or mutated (Mut) 3’UTRs downstream to the firefly 
luciferase gene were co-transfected into HEK293 cells together with Renilla luciferase 
control plasmid and either miR-146a or control (siGlo). Left, luciferase activity is given 
relative to activity in control-transfected cells. miR-146a reduced luciferase activity of 
constructs with WT CARD10, COPS8 and IRAK1 3’UTRs. Right, sequence alignments of 
miR-146a and potential WT and Mut 3’UTR target sites are shown, mutated bases are shown 
in red. Data are shown as mean ± S.D. often biological replicates. *** = P < 0.001. Sequence 
alignments are adapted from DIANALab (2009) 
miR-146a inhibits GPCR-mediated NF-κB activity by targeting CARD10 and 
COPS8 
CARD10 and COPS8 are involved in GPCR-mediated activation of NF-κB [28,29]. We 
therefore wanted to establish their roles in signal transduction in gastric cancer and 
subsequently investigate the importance of miR-146a for inhibiting this signaling. For this 
purpose we used lysophosphatiditc acid (LPA) which is a known activator of the GPCR-
mediated NF-κB-activation pathway [29], and promotes gastric cancer cell migration and 
invasion [37]. LPA-stiumlation significantly increased NF-κB activity in our luciferase 
reporter system (Figure 5). siRNA knockdown of CARD10 and COPS8 expression 
significantly inhibited LPA-stimulated GPCR-mediated activation of NF-κB in SNU638 cells 
(Figure 5). This inhibition was comparable to the miR-146a-induced inhibition. In contrast, 
inhibiting endogenous miR-146a was without effect on NF-κB activation. As predicted, 
siRNA-mediated repression of IRAK1 expression did not affect LPA-stimulated activation of 
NF-κB (Figure 5) as IRAK1 is not involved the GPCR-mediated pathway. As TRAF6 is a 
miR-146a target with a role in NF-κB activation, the effect of siRNA-mediated repression of 
TRAF6 expression on LPA-stimulated NF-κB activity was investigated. However, 
knockdown of TRAF6 did not inhibit LPA-stimulated NF-κB activity (Figure 5). These 
results indicate that the two newly identified miR-146a targets, CARD10 and COPS8, are 
involved in GPCR-mediated activation of NF-κB. Therefore, the effect of miR-146a over-
expression on LPA-stimulated NF-κB activity was studied. miR-146a significantly inhibited 
LPA-stimulated NF-κB activity in SNU638 cells (Figure 5). A mix of siRNAs against 
CARD10, COPS8, IRAK1 and TRAF6 mimicked the miR-146a-mediated inhibition of NF-
κB activity (Figure 5). Knockdown of two other COP9 components (COPS2 and COPS5) 
also inhibited the LPA-stimulated NF-κB activity, demonstrating the importance of presence 
of all COP9 signalosome subunits for LPA-stimulated activation of NF-κB. qPCR of the 
expression of the different components examined confirmed the knockdown (Figure 5). 
Figure 5 miR-146a targets COPS8 and CARD10 GPCR-mediated NF-κB activation. 
SNU638 cells were co-transfected with NF-κB reporter plasmid and Renilla luciferase 
control plasmid along with control (siGlo), siRNA or miR-146a. Cells were stimulated with 
25 μM LPA and luciferase activity was measured. Luciferase activity is given relative to 
activity in control transfected LPA-stimulated cells. siRNA against CARD10 and COPS8, 
miR-146a, miR-146a inhibitor and a siRNA mix reduced luciferase activity. siRNA against 
IRAK1 and TRAF6 did not reduce luciferase activity. LPA-stimulated NF-κB activation was 
also inhibited by siRNA against COPS2 and COPS5, demonstrating that other perturbation of 
the COP9 signalosome complex reduces GPCR-mediated NF-κB activation. siMix, mix of 
siRNAs against CARD10, COPS8, IRAK1 and TRAF6. Data are shown as the mean ± S.D. 
of seven biological replicates.* = P < 0.05. The relative expression of TRAF6, COPS8, 
IRAK1, CARD10, COPS2 and COPS5 was measured using qPCR. Gray-shading indicates a 
significant change in expression, p < 0.05, n = 4 
The expression of miR-146a is in part controlled by NF-κB. We therefore also tested how the 
expression of miR-146a was affected by LPA and IL-1β stimulation. We found that LPA 
treatment doubled the expression of miR-146a and IL-1β stimulation gave a 4-fold increase 
in miR-146a expression, which is comparable to earlier observations [16,38] (Additional file 
1: Figure S6). Although miR-146a LNA increased the expression of three of the miR-146a 
targets (TRAF6, IRAK1 and CARD10) (Figure 5) the overall activation of NF-κB was not 
altered in LPA-stimulated miR-146a LNA treated SNU638 cells. 
miR-146a reduces LPA-induced expression of cytokines and growth factors 
In most carcinomas microenvironmental factors rather than genetic alterations are probably 
responsible for activating NF-κB signaling that regulates several processes including 
secretion of growth factors and cytokines [39,40]. Therefore, we investigated how miR-146a 
modulates expression of selected NF-κB-regulated growth factors and cytokines induced by 
extracelluar signals such as LPA. LPA-stimulation significantly increased expression of 
interleukin-6, -8, 23A (IL-6, IL-8, IL-23A) and chemokine (C-C motif) ligand 5 (CCL5), 
colony stimulating factor 1 (macrophage) (CSF-1) and platelet-derived growth factor beta 
polypeptide (PDGFB) in SNU638 cells (Figure 6). This confirmed that expression of these 
genes is regulated by LPA-induced NF-κB activity. Over-expression of miR-146a 
significantly decreased expression of IL-8, IL-23A, CCL5, CSF-1 and PDGFB in SNU638 
cells (Figure 6). Even though IL-6 is a target gene of NF-κB, and also upregulated by LPA 
miR-146a over-expression did not reduce IL-6 expression under our conditions (Figure 6). 
However, LPA induction of IL-6 expression is not only mediated by NF-κB but also via other 
pathways (MAPK/ERK, PI3K/Akt, and p38) [41], which may contribute to the differences. In 
SNU638 cells the basal level of IL-6 is higher than IL-8, which may affect the mRNA 
turnover. This could be part of the reason that miR-146a has less effect on LPA-stimulated 
IL-6 expression than on IL-8 expression, which has also been seen in other cellular systems 
[42]. 
Figure 6 miR-146a inhibits LPA-induced cytokine expression. 25 μM LPA was used to 
induce cytokine expression from human gastric carcinoma SNU638 cells. LPA significantly 
enhanced expression of IL-6, IL-8, IL-23A, CCL5, CSF-1 and PDGFB, which was measured 
using qPCR and shown relative to the expression level in untreated control cells. This 
response is reduced in miR-146a-transfected cells. Data are shown as mean ± S.D., n = 4, 
* = P < 0.05, ns = non significant 
miR-146a over-expression in SNU638 cells reduces recruitment of monocytes 
In carcinomas monocytes can be recruited by e.g. CCL5 and CSF-1 expressed by tumor cells 
and this tumor infiltration of monocytes contributes to the tumor-promoting inflammatory 
response in the cancer [39,40]. Having demonstrated that miR-146a reduced LPA-induced 
expression of cytokines, we examined how miR-146a over-expression affected recruitment of 
monocytes. We found that LPA-treatment of SNU638 cells increased monocyte migration 
towards conditioned medium from the SNU638 cells (Figure 7 and Additional file 1: Figure 
S7), whereas transfection with miR-146a in part abrogated this response (Figure 7), again 
demonstrating that miR-146a inhibits the biological responses of GPCR-mediated activation 
of NF-κB such as, recruitment of monocytes. 
Figure 7 miR-146a reduces monocyte migration. Monocyte migration against conditioned 
medium from control- or miR-146a-transfected SNU638 cells that were left untreated or 
stimulated with 25 μM LPA was followed over 8 hours. Migration of cells is shown relative 
to migration of untreated control cells. Monocyte migration against medium from LPA-
stimulated SNU638 cells was increased compared to migration against medium from 
untreated cells, while monocyte migration against medium from miR-146a-transfected, LPA-
stimulated cells was decreased compared to medium from control-transfected, LPA-
stimulated cells. Data are shown as mean ± S.D. of four biological replicates. ** = P < 0.01, 
ns = non significant 
Discussion 
Microenvironmental factors are important for NF-κB activation in inflammation-driven 
cancers such as gastric cancer and this NF-κB activation may provide cancer cells with 
advantages, which contribute to the tumorgenic processes [32,43]. Modulation of NF-κB-
activating signaling is therefore important for controlling inflammation-mediated tumor 
development. Here, we show that miR-146a is a central negative regulator of NF-κB 
activation as it inhibits several NF-κB-activating pathways. 
miR-146a expression was found up-regulated in app. 2/3 of the human gastric 
adenocarcinomas as well as in the gastrin KO mouse model of gastric cancer. Similarly, 
expression of miR-146a has been found increased in cervical, breast, pancreatic and thyroid 
cancer [11,44-46]. Previously, expression of miR-146a has been found both up- and down-
regulated in gastric cancer [21-24]. These conflicting results may reflect differences in 
tumors and their microenvironment resulting in different degrees of NF-κB activities, which 
controls miR-146a expression [16]. Surprisingly, we found low levels of miR-146a in human 
gastric cancer cell lines. This could indicate that the increased miR-146a levels seen in 
tumors are coursed by microenvironmental factors e.g. cells surrounding the tumor cells. 
To examine the effects of increased miR-146a levels in gastric cancer we identified two new 
miR-146a targets, CARD10 and COPS8, and investigated the roles of these targets. We found 
that miR-146a inhibited GPCR-mediated NF-κB activation by directly targeting and down-
regulating expression of CARD10 and COPS8. CARD10 is known to be required for GPCR-
induced activation of NF-κB [27,29], while COPS8 is a subunit of COP9 signalosome that 
controls NF-κB activation [28,47]. We showed that CARD10 is involved in GPCR-mediated 
activation of NF-κB, and provided new evidence that COPS8 is involved in this pathway as 
well. miR-146a over-expression also led to reduced expression of COPS2, another subunit of 
the COP9 signalosome. We assume that this is an indirect effect, since there is no miR-146a 
binding site in COPS2 3’UTR and changes in the expression of one subunit has been shown 
to affect that of the other [35,36]. It is therefore possible that miR-146a to some extent may 
act by not only targeting COPS8 but destabilizing the COP9 signalosome. 
Aberrant signaling through GPCRs has been linked to tumor cell growth and survival, and 
NF-κB-activating GPCRs have been shown to contribute to a wide range of cancers 
(reviewed by Dorsam & Gutkind [48]). GPCRs can activate NF-κB via the 
CARD10/BCL10/MALT1 complex after binding ligands such as LPA, enothelin-1, 
angiotensin II (Ang II) and chemokine (C-X-C motif) ligand 12 (CXCL12) (Figure 8) 
[29,49]. In our study we used LPA to model GPCR-mediated activation of NF-κB. LPA-
induced GPCR-signaling leads to tumor progression [49]. Thus, miR-146a-mediated 
inhibition of GPCR-signaling could have tumor suppressing effects. 
Figure 8 miR-146a targets multiple NF-κB activation pathways. Schematic illustration of 
NF-κB-activating pathways. miR-146a has previously been shown to target IRAK1 and 
TRAF6 and in this study we show that miR-146a targets CARD10 and COPS8. miR-146a 
targets are marked with red circles 
In addition to GPCR-mediated NF-κB activation, NF-κB can be activated via tumor-necrosis-
factor receptor (TNFR), IL-1R, TLR, TCR and B cell receptor (BCR) [50] (Figure 8). 
Previously, miR-146a has been shown to inhibit NF-κB activation via these receptors by 
down-regulating expression of TRAF6 and IRAK1 [16,18,30,31]. miR-146a targets IRAK1 
in gastric cancer cells, but not TRAF6. Although, we here show that miR-146a targets 
GPCR-mediated activation of NF-κB, in addition to the activation via TNFR, IL-1R, TLR, 
TCR and BCR, by targeting CARD10 and COPS8 (Figure 8). Thus, miR-146a targets 
multiple components of NF-κB-activating pathways in gastric cancer cells. This has not been 
shown for the NF-κB pathway before, but has previously been seen in the transforming 
growth factor-β (TGF-β) pathway, where both miR-21 and the miR-17-92 cluster target 
several mRNAs coding for proteins in the TGF-β pathway [51,52]. By targeting multiple 
components of different NF-κB-activating pathways miR-146a mediates a robust and 
complex control of NF-κB activity. Several other miRNAs can also regulate NF-κB-
signaling, but only miR-146a targets several genes in different NF-κB-activating pathways, 
suggesting miR-146a as a key modulator of NF-κB activation. 
NF-κB regulates expression of cytokines and growth factors involved in several aspects of 
tumor progression [43]. Given that miR-146a decreases NF-κB activity, it is possible that 
miR-146a acts tumor suppressing by reducing expression of such cytokines and growth 
factors. Indeed, we found that miR-146a over-expression reduced expression of several 
cytokines and growth factors with a known role in cancer development; IL-8, IL-23A, CCL5, 
CSF-1 and PDGFB. These genes can increase cell proliferation, cell adhesion and 
angiogenesis [53-55], contribute to tumor lymphangiogenesis [56], activate fibroblasts [57], 
recruit monocytes to tumors [39,40] and induce tumor-associated macrophages (TAMs) to 
secrete tumor-promoting mediators [58] (Figure 9). 
Figure 9 Biological processes in gastric cancer cells inhibited by miR-146a. Left panel, 
miR-146a directly targets IRAK1, CARD10 and COPS8 in SNU638 cells. This leads to 
inhibition of NF-κB activation and consequently to repressed expression of NF-κB-regulated 
cytokines and growth factors. Expression of miR-146a is also regulated by NF-κB [16]. Right 
panel, miR-146a decreases expression of CCL5, CSF-1, IL-8, PDGF and IL-23A, which are 
involved in monocyte migration and differentiation, proliferation, angiogenesis, 
lymphangiogenesis and fibroblast and macrophage growth factor release. Thus, miR-146a 
might act as a tumor suppressor by reducing cancer-promoting effects of NF-κB activity 
Chemotactic cytokines released by tumor cells can recruit monocytes to tumor sites [39,59]. 
These monocytes can promote tumor progression [60]. CCL5 and CSF-1 are examples of 
monocyte-recruiting cytokines released by tumor cells [39,40]. As expected, monocytes 
migrated less against conditioned medium from LPA-stimulated SNU638 cells over-
expressing miR-146a compared to LPA-stimulated control cells. Thus, miR-146a may reduce 
tumor infiltration of monocytes by decreasing tumor cell expression of cytokines. 
Up-regulated levels of miR-146a in gastric cancer seen in this study could be caused by 
increased NF-κB activity in tumor cells. miR-146a is part of a negative feedback loop that 
inhibits NF-κB activation in gastric cancer and the subsequent tumor-promoting processes. 
This is supported by a recent study that found low expression of miR-146a associated with 
poor survival of gastric cancer patients [22]. 
Conclusions 
In summary, we have identified two new targets of miR-146a, CARD10 and COPS8 that are 
both involved in GPCR-mediated activation of NF-κB, and we have found that miR-146a 
inhibits secretion of chemokines and growth factors controlled by NF-κB. With the addition 
of two new miR-146a targets we have shown that this miRNA targets several signal 
transduction pathways that activate NF-κB. Hence, we suggest that miR-146a act tumor-
suppressing by inhibiting NF-κB activity and the consequently expression of tumor-
promoting cytokines and growth factors. 
Methods 
Mice 
Groups of WT and gastrin KO mice aged 1½ years were used. The mice were on a mixed 
129/SvJ, C57BL/6J background backcrossed at least four times to C57BL/6J [25]. The mice 
were sacrificed by cervical dislocation. The stomachs were removed, washed gently in ice-
cold PBS and the fundus was dissected from the stomach, frozen in liquid nitrogen and stored 
at −80°C until RNA extraction. The mice were kept under specific pathogen-free conditions 
and monitored according to the Federation of European Laboratory Animal Science 
Associations recommendation [61]. The studies were approved by the Danish Animal 
Welfare Committee (2005/562-40) and the Danish Forest and Nature Agency 
(20010077355/6). 
Human tissue samples 
Biopsies from human gastric adenocarcinomas and adjacent normal tissue were obtained 
from patients who underwent surgical resection at the Department of Gastrointestinal 
Surgery, Rigshospitalet, Copenhagen, Denmark, between July and December 2008. 
Collection of gastric cancer biopsies was approved by the Danish Ethical Committee (journal 
H-B-2008-049) and the establishment of a biobank was approved by Danish Data Protection 
Agency (journal 2008-41-2138). All procedures were in accordance with institutional ethical 
standards. All individuals provided written informed consent, and all samples were delinked 
and unidentified from their donors 
Cell culture and transfections 
SNU638 cells were grown in RPMI1640 medium (Invitrogen, Carlsbad, CA) and HEK293 
cells in DMEM + GlutaMAX™-I (Invitrogen), both supplemented with 10% Fetal Bovine 
Serum (Biowest, Nuaillé, France), penicillin (100 U/ml), streptomycin (100 μg/ml) (Sigma-
Aldrich, Saint Louis, MI) and cefotaxim (100 μg/ml) (ACS Dobfar Generics S.A., 
Luxembourg, Belgium). Cells were cultured at 37°C in 5% CO2. Where nothing else is stated 
cells were transfected using Turbofect™ in vitro Transfection Reagent (Fermentas GmbH, St. 
Leon-Rot, Germany). To over-express miR-146a in cultured cells 50 nM Pre-miR™ miRNA 
Precursors for human miR-146a (hsa-miR-146a, Ambion, Invitrogen) were used and 50 nM 
siGlo (Dharmacon, Lafayette, CO) were used as negative control. 
RNA isolation 
Where nothing else is stated total RNA from tissue and cells was isolated using TRIzol® 
Reagent (Invitrogen). 
miR-146a over-expression analysis 
For mRNA microarrays SNU638 cells were transfected with miR-146a or siGlo using 
Lipofectamine2000 (Invitrogen). 24 h post-transfection total RNA was isolated. Affymetrix 
microarray analysis was performed at the Microarray Center, Rigshospitalet, Copenhagen, 
Denmark, using HG-U133 Plus 2.0 human arrays (Affymetrix, Santa Clara, CA) as 
previously described [62] and predicted miR-146a target genes were identified [63]. Briefly, 
2 μg of total RNA was used to synthesize double-stranded cDNA using Superscript Choice 
System (Invitrogen) with an oligo(dT) primer containing a T7 RNA polymerase promoter. 
Subsequently, cDNA was used as template for an in vitro transcription reaction generating 
biotin-labeled antisense cRNA (BioArrayTM High Yield RNA Transcript Labeling kit; Enzo 
Diagnostics, Farmingdale, NY). Arrays were scanned in an Affymetrix GeneArray® 2500 
scanner and data were analyzed using D-chip MFC Application (software version 1.0.0.1). 
Three biological replicates of each transfection were analyzed. The microarray expression 
data were processed using the 'affy' package in BioConductor. Probeset intensities were 
summarized and quantile normalized using the RMA and VSN packages. Differential 
expression was determined per probe set using a t-test. The probe sets were mapped to 
Ensembl transcripts (version 49) using mappings obtained from BioMart. Probe sets that 
mapped ambiguously to different Ensembl genes were discarded. 3’UTRs were scanned for 
matching 6mer, 7mer and 8mer miR-146a target sites (complementary to position 2–7, 2–8, 
and 2–9 of the miRNA sequence). To evaluate if predicted miR-146a targets were down-
regulated after miR-146a transfection, we tested the null hypothesis that the expression 
change distribution of predicted miR-146a target genes (having a 7mer target site in the 
3’UTR) was identical to the distribution of all expressed genes without predicted target sites 
using the non-parametric Wilcoxon rank-sum test. We used a previously published non-
parametric rank-based statistic to perform an exhaustive and unbiased assessment of the 
correlation of 3’UTR word occurrences and the change in gene expression after miR-146a 
transfection [63]. Genes were sorted by their expression change after miR-146a transfection, 
and the correlation with down-regulation was tested for all words of length 5–7 (N = 21504). 
Quantitative PCR 
Mature miR-146a expression was measured and quantified using TaqMan® MicroRNA 
Assay hsa-miR-146a (Applied Biosystems, Foster City, CA). For each biological sample 
technical triplicates were made. Analyses were carried out on the ABI Prism® 7900HT 
Sequence Detection System (SDS) (Applied Biosystems). miR-146a levels were normalized 
to the endogenous control RNU44 (Applied Biosystems). 
For mRNA qPCR, total RNA from transfected cells was isolated and qPCR was performed 
using SuperScript™ III First-Strand Synthesis SuperMix (Invitrogen) and SYBR GreenER™ 
qPCR SuperMix for ABI PRISM® (Invitrogen). The analyses were carried out on ABI 
Prism® 7900HT SDS (Applied Biosystems). Primers were designed using primer3 
(Additional file 1: Table S1) or predesigned primers (Quantitect, Qiagen, Hilden, Germany) 
were used. For each biological sample technical triplicates were made. Expression of target 
mRNA was normalized to GAPDH expression and quantified using standard curves. 
In situ hybridization 
Gastric tissues from WT and gastrin KO mice were formalin-fixed and paraffin-embedded 
(FFPE). FFPE tissue samples of human gastric adenocarcinomas and normal gastric tissues 
were obtained from the Department of Pathology, Rigshospitalet, Copenhagen, Denmark. A 
DIG-labeled mercury locked nucleic acid miR-146a detection probe (Exiqon, Vedbæk, 
Denmark) was used for detection as described by Jørgensen et al. [64]. Probe concentration 
was 100 nM and slides were hybridized at 50°C. Pictures of representative areas of the slides 
were taken with a Zeiss Axio Imager (Zeiss, Jena, Germany), original magnification x20/10. 
Cells with intense blue nuclear stain were scored as positive. The level of expression within a 
positive cell was not scored. A LNA probe against snRNA U6 (Exiqon) was used as positive 
control and a scramble probe (Exiqon) as negative control. 
Western blotting 
For Western blotting SNU638 cells were transfected with miR-146a or siGlo and cells were 
harvested 6 and 72 h post-transfection. Proteins were separated on polyacrylamide gels, 
transferred to nitrocellulose membranes, incubated with antibodies against IRAK1 (4359, 
Cell Signaling Technology, Danvers, MA), CARD10 (ab64171, abcam, Cambridge, UK), 
COPS8 (ab77300, abcam) or β-actin (A2228, Sigma-Aldrich) and visualized by 
chemiluminescence (SuperSignal® West Pico, Pierce, Rockford, IL) using LAS-1000 Pro v. 
2.6 (FujiFilm, Tokyo, Japan). Protein band intensities were quantified using Multi Gauge 
Software v. 3.1 (FujiFilm). β-actin was used as loading control. 
3’UTR luciferase assay 
3’UTR luciferase reporter plasmids were constructed by amplifying CARD10 and COPS8 
3’UTR fragments containing potential miR-146a binding sites from human genomic DNA 
(primer sequences in Additional file 1: Table S2). Fragments were cloned into pMIR-
REPORT Luciferase miR Expression Reporter Vector (Applied Biosystems) downstream of 
the Firefly luciferase gene. miR-146a seed sites were mutated by substitution of four 
nucleotides using QuickChange Site-Directed Mutagenesis Kit (Agilent Technologies, Palo 
Alto, CA), thereby changing the sequence from AGTTCTCA to AGAAGACA (mutagenesis 
primers in Additional file 1: Table S3). pMIR-REPORT plasmids containing WT and 
mutated IRAK1 3’UTR site were made by Taganov et al. [16] (Addgene plasmids 
15095/15096). HEK293 cells were plated at 1x10
5
 cells/well in 24-well plates and transfected 
24 h later. HEK293 cells were used as they generally have low endogenous miRNA levels 
[65]. Each transfection reaction contained 10 ng luciferase pMIR-REPORT and 20 ng Renilla 
vector (pRL-TK, Promega, Madison, WI) together with 50 nM miR-146a (Ambion) or siGlo 
(Dharmacon). 24 h post-transfection Firefly luciferase and Renilla luciferase luminescence 
was measured using Dual-Glo luciferase kit (Promega) and a GloMax®-96 luminometer 
(Promega). Background measurements were subtracted and ratios of Firefly luciferase 
luminescence from pMIR-REPORT relative to Renilla luciferase luminescence from pRL-TK 
were calculated. 
NF-κB activity assay 
SNU638 cells were plated at 1x10
5
cells/well in 24-well plates and transfected after 24 h. 
Each transfection reaction contained 500 ng NF-κB luciferase reporter plasmid [66], 50 ng 
pRL-TK (Promega) and 50 nM siGlo (Dharmacon), 50 nM miR-146a (Ambion), 50 nM 
miCURY miR-146a inhibitor (Exiqon) or 50 nM siRNAs against CARD10, COPS8, IRAK1 
or TRAF6 (Flexitube, Qiagen, Hilden, Germany). 24 h post-transfection cells were stimulated 
with 25 μM LPA (Avanti Polar Lipids, Alabaster, AL). 24 h after stimulation Firefly 
luciferase and Renilla luciferase luminescence was measured as described above. 
Background measurements were subtracted and ratios of luminescence from NF-κB reporter 
plasmid relative to luminescence from pRL-TK were calculated. 
Monocyte migration 
Monocytes were isolated by density gradient centrifugation followed by plastic adherence. 
Peripheral blood mononuclear cells were isolated from blood from healthy donors by density 
centrifugation with Lymphoprep using a standard protocol (Axis-Shield Poc AS, Oslo, 
Norway) [67]. Cells were plated in plastic dishes and allowed to adhere for 1 h. Non-adherent 
cells were washed away and adherent monocytes were used for migration studies. Monocytes 
were seeded in the upper chambers of CIM-plate 16 (Roche Diagnostics GmbH, Manheim, 
Germany). 8x10
5
 cells/well were seeded in RPMI1640 medium containing 1%. Lower 
chambers contained conditioned medium from siGlo- or miR-146a-transfected SNU638 cells 
that were left untreated or treated with 25 μM LPA (Avanti Polar Lipids) for 6 hours. 
Migration was followed real-time over 8 hours with xCELLigence impedance analysis using 
the RTCA DP instrument (Roche Diagnostics GmbH). This method allows continuous 
measurement of cell migration by measuring the electrical impedance over gold electrodes 
incorporated on the underside of a microporous polyethylene terephthalate dividing an upper 
and lower. Migration rates were calculated using the RTCA software (Roche Diagnostics 
GmbH). 
Statistical analysis 
Where nothing else is stated statistical analyses were performed using Student’s unpaired 
two-tailed t-test calculated by Excel’s ToolPak or GraphPad Prism Software. P-values less 
than 0.05 were considered significant. The patient overall survival from the day of surgery 
was examined using the Kaplan-Meier method, with log-rank test (Mantel-Cox test) and the 
Gehan-Breslow-Wilcoxon test for statistical significance. 
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Additional file 1 Figure S1. Expression of miR-146a in the gastrin KO mice and in 
human gastric cancer. In situ hybridization detection of miR-146a expression. (A and B) 
miR-146a expression was absent in WT fundic mouse tissue, while miR-146a-positive cells 
(blue nuclei) were detected in the metaplastic fundic tissue from gastrin KO mice. (C and D) 
miR-146a expression was absent in normal human gastric tissue, while human gastric 
adenocarcinoma cells stained for miR-146a (blue nuclei). Original magnification x10, Scale 
bar = 100 μm. (PDF 1343 kb). Figure S2. Survival of gastric cancer patients with low or 
high tumor miR-146a expression. Kaplan-Meier overall survival curves according to miR-
146a level. Although patients whose tumors have high expression of miR-146a seemed to 
have better survival than those with low expression, it was not significant, p = 0,31 (Mantel-
Cox Test). Low expression was defined as those with a relative miR-146a expression below 
the median expression and high expression had relative expression above median. Figure S3. 
Relative expression of miR-146a in cell lines. The expression of miR-146a in cells lines 
determined by qPCR. Gastric cancer cell lines are indicated by red bars. Relative miR-146a 
expression was determined using TaqMan® MicroRNA Assay hsa-miR-146a according to 
the manufacturer’s protocol (Applied Biosystems). miR-146a levels were normalized to hsa-
miR-191 (Applied Biosystems), which served as an endogenous control. Figure S4. Normal 
growth of SNU638 cells transfected with miR-146a in cell lines. 2,5 106 SNU638 cells 
were seeded in 10 cm petri dishes and transfected the following day with 50 nM miR-146a, 
miCURY miR-146a inhibitor or Ctrl using Lipofectamine 2000 (Invitrogen). The following 
day the cell were transferred to 24-well plates where the cells were fixed at indicated time 
points in 4% paraformaldehyde, stained in a 0.1% crystal violet solution, and resuspended in 
10% acetic acid. Sample absorbance was measured at 620 nm, and normalized to that of 
siGlo control transfected cells. Mean ± S.D. n = 4 /day. Figure S5 Expression of the 
mammalian signalosome 8 subunits (GPS1 and COPS2-8) in SNU638 cells transfected 
with miR-146a. Alteration in the expression of one subunit has been reported to affect the 
expression of the others. Using qPCR the expression of the subunits (GPS1 and COPS2-8) 
was therefore examined in SNU638 cells transfected with miR-146a. Only COPS8 mRNA is 
a direct target of miR-146a, indicated by open bars. The absence of miR-146a target sites is 
indicated by closed bars. The expression of COPS8 and COPS2 was reduced following miR-
146a transfection. Mean ± S.D. * = p < 0.05, n = 4. COPS8 mRNA is directly targeted by miR-
146a, while we assume that the expression of COPS2 is indirectly affected by miR-146a 
since the mRNA does not contain a miR-146a target site. Figure S6. Up-regulation of miR-
146a in response to cancer-related cytokines. SNU638 cells were grown in media with 1% 
FCS overnight and subsequently stimulated with either LPA (10 μM), IL-1β (10 ng/ml) or 
vehicle for 6 h. The expression of miR-146a was measured by qPCR and normalized to the 
expression of U44. miR-146a expression is shown relative to the average expression in the 
control. Data are the mean ± S.D. (n = 4). Figure S7 Monocyte migration Boyden chamber 
assay. Monocyte migration against conditioned medium from control- or miR-146a-
transfected SNU638 cells that were left untreated or stimulated with 25 μM LPA was 
followed over 6 hours. Monocyte migration against medium from LPA-stimulated SNU638 
cells was increased compared to migration against medium from untreated cells, while 
monocyte migration against medium from miR-146a-transfected, LPA-stimulated cells was 
decreased compared to medium from control-transfected, LPA-stimulated cells. Data are 
shown as mean ± S.D, n = 3, * = P < 0.05. Monocytes were isolated as described. Monocytes 
were seeded in the upper chambers of Boyden chamber assay (Becton Dickinson, Heidelberg, 
Germany), 2.5x104 cells/well were seeded in RPMI1640 medium containing 1%. The lower 
chambers contained conditioned medium from SNU638 cells that had been transfected with 
Ctrl, miR-146a, or miCURY-miR-146a inhibitor and the following day left untreated or 
treated with 25 μM LPA (Avanti Polar Lipids) for 6 hours (n = 3). After 120-minute 
incubation in 5% CO2 at 37°C, non-migrating cells were scraped from the upper surface of 
the filter using a cotton plug. Cells on the lower surface were fixed with methanol and stained 
with methylene blue. The number of cells on the lower surface of the filter was determined 
microscopically by counting 3 high-power (x400) fields of constant area per well. To 
normalize all experiments, values were expressed as the fraction of number of cells that 
migrated through in the unconditioned control. Mean ± S.D. Table S1 mRNA qRT-PCR 
primers (TAG Copenhagen, Copenhagen, Denmark). Table S2 3’UTR luciferase primers. 
Restriction sites are indicated with lower case lettters (TAG Copenhagen). Table S3 
Mutagenesis primers. Table 4 Transcripts with predicted 3’UTR miR-146a target sites that 
were significantly down-regulated upon miR-146a transfection. 
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